Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional) | PAR 18 554

Opportunity Information: Apply for PAR 18 554

The National Institutes of Health (NIH) funding opportunity titled "Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)" supports early-stage, higher-risk research aimed at testing a central idea in modern neuroscience and psychiatry: that healthy cognition, emotion, and social behavior depend on well-coordinated patterns of neural activity across brain circuits, and that deliberately changing those patterns during behavior may improve cognitive, affective, or social functioning. The announcement highlights coordinated electrophysiological phenomena such as brain oscillations (rhythms), interactions between rhythms at different frequencies (cross-frequency coupling), relationships between neuronal spiking and oscillation phase (spike-phase correlations), and coordinated population-level spiking dynamics. The longer-term motivation is therapeutic discovery for neuropsychiatric disorders where cognition, mood, or social processes are disrupted, by using measurable, manipulable neural dynamics as intervention targets rather than relying only on symptom-level outcomes.

The FOA specifically requires experimental designs that include active manipulation, meaning applicants should not simply observe correlations between neural signals and behavior. Instead, projects need to intervene in a way that can plausibly change temporal coordination in neural activity and then test whether that change leads to improvements in cognitive performance, emotional regulation, or social processing. The emphasis is on causal tests: if you alter a defined neural coordination parameter, does a specific behavioral or clinical-relevant function measurably improve, and under what conditions does it not? This orientation toward causality makes room for approaches like stimulation, closed-loop neuromodulation, optogenetic or chemogenetic manipulation in animals, pharmacological perturbations that affect circuit dynamics, behavioral manipulations paired with neural control strategies, or other methods that can directly shift the timing and coordination of neural activity while subjects perform relevant tasks.

Applications are expected to address at least one, and preferably more than one, of four core topic areas. First, the FOA encourages studies in animals or humans that isolate particular parameters of neural coordination and test which ones matter for which functions. In practice, this means going beyond broad statements like "theta is important" and instead identifying concrete, quantifiable features (for example, oscillation frequency, phase locking strength, coherence between regions, burst timing, cross-frequency coupling metrics, or population trajectory structure) and testing whether manipulating one feature at a time improves a targeted aspect of cognition, affect, or social behavior. Second, the FOA invites work linking lower-level biological abnormalities to systems-level coordination, asking how genomic, molecular, or cellular disruptions translate into altered brain-wide electrophysiological coordination during behavior. This creates a bridge between mechanisms at the level of genes, synapses, and cell types and the larger-scale timing relationships observed in networks, aligning well with translational neuroscience goals.

Third, the opportunity highlights cross-species and translational prediction: determining whether in vivo systems-level electrophysiological changes in behaving animals can predict analogous electrophysiological and cognitive improvements in healthy humans or clinical populations. In other words, NIH is encouraging applicants to build evidence that animal-based circuit interventions and their electrophysiological signatures are not just interesting within a single model, but informative for human neuroscience and potentially for treatment development. This can include identifying homologous neural signatures (such as similar coordination metrics across species), using tasks that are meaningfully comparable, and specifying what counts as an "analogous" improvement at both the neural and behavioral level. Fourth, the FOA supports biologically realistic computational modeling that incorporates systems-level dynamics to explain how these oscillatory and electrophysiological patterns emerge over time and across brain regions, and how they influence cognition, affect, and social processing. Importantly, modeling here is not meant to be purely abstract; it is framed as a tool for understanding function and mechanism in a way that connects to real neural measurements and manipulations.

Mechanistically, the announcement positions coordinated neural activity as a potentially actionable intervention target. Rather than treating oscillations or synchrony as passive biomarkers, the FOA treats them as candidate control variables that might be tuned to improve function. This includes the idea that disorders may involve disrupted timing relationships between regions or cell populations, and that restoring or reshaping those temporal dynamics could improve downstream processing. The behavioral emphasis is also notable: electrophysiological patterns are to be modified during behavior, linking changes in neural timing directly to performance or symptom-relevant measures, which strengthens interpretability and translational value.

From a grants standpoint, this opportunity uses the NIH R21 mechanism, which is designed for exploratory, developmental projects. R21 awards are generally shorter in duration and are meant to support high-risk, high-reward studies, pilot data generation, and early testing of novel ideas or methods that may later justify a larger R01-level project. The FOA notes that there is a companion funding opportunity using the R01 mechanism for more mature, extensive projects, reinforcing that the R21 is intended for focused, proof-of-concept work. The listing specifies an award ceiling of $200,000, indicating the maximum budget level associated with this opportunity as provided in the source data. The clinical trial designation is "optional," meaning applicants may propose studies that include clinical trials if appropriate, but they are not required to do so, and non-trial mechanistic or translational studies are also within scope.

Eligibility is broad and includes a wide range of U.S. organizations and institutions, such as state and local governments, tribal governments and tribal organizations, public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses. The FOA also explicitly mentions additional eligible applicant types, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This broad eligibility reflects NIH interest in drawing from diverse research environments, populations, and expertise, which is often critical for advancing translational neuroscience.

Key administrative details from the source information include the funding opportunity number PAR-18-554, classification as a discretionary grant under the health activity category, and association with CFDA number 93.242. The agency is NIH, the opportunity was created on 2018-01-02, and the original closing date listed is 2021-03-16. Overall, the FOA is best understood as an NIH invitation to run tightly designed, manipulation-focused studies that treat coordinated neural dynamics as causal levers for improving cognition, emotion, and social function, while also encouraging mechanistic links across biological scales and improved translation between animal models, computational accounts, and human outcomes.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
• This funding opportunity was created on 2018-01-02.
• Applicants must submit their applications by 2021-03-16. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $200,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 18 554

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: